Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 7,594 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bones Clear all
Completed No phase listed Observational

Screening of Bone Mineral Density in Women Who Have Received Chemotherapy

NCT00603551
View directory record Official record
Conditions
Bone Density, Cancer
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Nov 5, 2026, 6:32 AM EST
Completed Not applicable Interventional Results available

Epidural Lavage Study for Lumbar Stenosis

NCT03511053
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Epidural Steroid Injection with Lavage
Procedure
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Nov 5, 2026, 6:32 AM EST
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

NCT00008177
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
Interventions
iodine I 131 monoclonal antibody BC8, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, fludarabine phosphate, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
Radiation · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Nov 5, 2026, 6:32 AM EST
Not listed Not applicable Interventional

Intra-operative Assessment of the Intellirod LOADPRO Spinal Rod Strain Sensor for Use During Kyphotic Corrective Surgery

NCT02768675
View directory record Official record
Conditions
Kyphosis, Spinal Fractures
Interventions
LOADPRO
Device
Lead sponsor
Intellirod Spine
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Louisville, Kentucky • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Nov 5, 2026, 6:32 AM EST
Not listed No phase listed Observational

InterFuse® S and T for the Treatment of Scoliosis, Spondylolisthesis and Degenerative Disc Disease (DDD)

NCT02659722
View directory record Official record
Conditions
Scoliosis, Back Pain
Interventions
InterFuse
Device
Lead sponsor
Vertebral Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 5, 2026, 6:32 AM EST
Completed Not applicable Interventional

The Effect of Touch on Pain and Anxiety During the Bone Marrow Biopsy Procedure

NCT04935775
View directory record Official record
Conditions
Pain, Acute, Anxiety
Interventions
Untrained Touch
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 5, 2026, 6:32 AM EST
Active, not recruiting Phase 1 Interventional

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

NCT04420975
View directory record Official record
Conditions
Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Resectable Dedifferentiated Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Soft Tissue Fibrosarcoma, Spindle Cell Sarcoma, Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Retroperitoneal Sarcoma AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Retroperitoneal Sarcoma AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage II Retroperitoneal Sarcoma AJCC v8, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Retroperitoneal Sarcoma AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Retroperitoneal Sarcoma AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Storiform-Pleomorphic Malignant Fibrous Histiocytoma, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Undifferentiated Pleomorphic Sarcoma, Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells, Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant, Undifferentiated Spindle Cell Sarcoma
Interventions
Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab, Radiation Therapy
Procedure · Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 5, 2026, 6:32 AM EST
Completed Phase 2 Interventional

High-dose ICE With Amifostine

NCT00003657
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Nov 5, 2026, 6:32 AM EST
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

NCT00455312
View directory record Official record
Conditions
Dyskeratosis Congenita, Aplastic Anemia
Interventions
Campath 1H, Cyclophosphamide, Fludarabine, Total Body Irradiation, Stem Cell Transplantation, antithymocyte globulin, Methylprednisolone
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Nov 5, 2026, 6:32 AM EST
Recruiting Phase 1 Interventional

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

NCT06218628
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia, Polycythemia Vera, Essential Thrombocytosis
Interventions
Talazoparib, pacritinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Nov 5, 2026, 6:32 AM EST
Recruiting Phase 3 Interventional

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

NCT03394365
View directory record Official record
Conditions
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions
tabelecleucel
Biological
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 6:32 AM EST
Enrolling by invitation Phase 1Phase 2 Interventional

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

NCT01852370
View directory record Official record
Conditions
Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, Severe Chronic Neutropenia, Chronic Granulomatous Disease (CGD), Hyper IgE Syndromes, Hyper IgM Deficiencies, Wiskott-Aldrich Syndrome, Mendelian Susceptibility to Mycobacterial Disease, Common Variable Immune Deficiency (CVID)
Interventions
CD3/CD19 negative allogeneic hematopoietic stem cells
Biological
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 5, 2026, 6:32 AM EST
Completed Not applicable Interventional

The Impact of Arts-Based Interventions on Patient Hospital Experience

NCT04024670
View directory record Official record
Conditions
High Risk Pregnancy, Bone Marrow
Interventions
Arts Intervention
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Nov 5, 2026, 6:32 AM EST
Active, not recruiting Phase 1 Interventional

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

NCT06034470
View directory record Official record
Conditions
Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography, Fludarabine, Granulocyte Colony-Stimulating Factor, Idarubicin, Multigated Acquisition Scan, Pivekimab Sunirine
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 5, 2026, 6:32 AM EST
Terminated Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

NCT00020969
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
arsenic trioxide
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
8
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Nov 5, 2026, 6:32 AM EST
Terminated Phase 1Phase 2 Interventional Results available

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

NCT02712905
View directory record Official record
Conditions
Solid Tumors and Hematologic Malignancy
Interventions
INCB059872, all-trans retinoic acid (ATRA), azacitidine, nivolumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 5, 2026, 6:32 AM EST
Terminated Phase 3 Interventional Results available

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

NCT00362466
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib, Imatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
45
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Alhambra, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Nov 5, 2026, 6:32 AM EST
Completed Phase 2 Interventional Results available

Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

NCT00433745
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)
Interventions
WT1 Peptide Vaccine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Nov 5, 2026, 6:32 AM EST
Terminated Phase 1 Interventional

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

NCT00089245
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions
Iodine I 131 MOAB 8H9
Drug
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
Not listed
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Nov 5, 2026, 6:32 AM EST
Completed Phase 1 Interventional Results available

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

NCT02011945
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Dasatinib, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Nov 5, 2026, 6:32 AM EST
Completed Phase 4 Interventional Results available

Zoledronic Acid Administration in Acute Spinal Cord Injury

NCT02042872
View directory record Official record
Conditions
Disuse Osteoporosis
Interventions
Zoledronic acid
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 49 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Nov 5, 2026, 6:32 AM EST
Completed Phase 3 Interventional

Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies

NCT02566395
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Radiation, Cyclophosphamide, Donor Lymphocyte Infusion (DLI), Haploidentical Stem Cell Transplantation
Radiation · Drug · Biological
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Nov 5, 2026, 6:32 AM EST
Completed Phase 4 Interventional

The Influence of Dimensional Anatomic Variables on the Outcomes of Maxillary Sinus Grafting Procedures

NCT00868777
View directory record Official record
Conditions
Edentulism, Alveolar Bone Atrophy, Sinus Pneumatization
Interventions
Sinus grafting using allogenic bone
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Nov 5, 2026, 6:32 AM EST
Completed Phase 2 Interventional

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

NCT04232657
View directory record Official record
Conditions
Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
Interventions
Romosozumab, Denosumab, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 5, 2026, 6:32 AM EST